The Procter Gamble Company

Precisionbiotics Group Limited

Wenzhu Zhao

Tomohiro Hakozaki

Jun Xu

Leo Timothy Laughlin, Ii

Robert Lloyd Binder

John Christian Haught

Liam Diarmuid O'Mahony

Yakang Lin

Duane Larry Charbonneau

Charles Carson Bascom

Douwe Van Sinderen

Christine Marie Cahen

Karen Kay Kalla

Karen Marie Osorio

John Crist Bierman

Raymond Alan Grant

Bradley Bryan Jarrold

Koti Tatachar Sreekishna

Yuli Song

Cathy Renee Schinaman

Jiazhen Wang

Leo Timothy Laughlin

Leo Timothy Ii Laughlin

The multiple embodiments described herein comprise the genome of a probioticbifidobacteria strain and genes encoded by the genome. Various novelare described.

A method of generating a hyperpigmentation condition gene expression signature for use in identifying connections between perturbagens and genes associated with a skin pigmentation condition. The method includes providing a gene expression profile for a reference sample of human skin cells not affected with a pigmentation condition; generating a gene expression profile for a sample of human skin cells from a subject exhibiting the hyperpigmentation condition; comparing the expression profiles to determine a gene expression signature that includes a set of differentially expressed genes; assigning an identifier to each gene constituting the gene expression signature and ordering the identifiers according to the direction of differential expression to create one or more gene expression signature lists; and storing the one or more gene expression signature lists on at least one computer readable medium.

Method of generating a hyperpigmentation condition gene expression signature

A method of formulating a skin-lightening composition by identifying actives with a data architecture and incorporating the actives into a skin care composition. The data architecture can be used to identify connections between perturbagens and genes associated with skin tone. A gene expression profile for a control human cell is compared to the gene expression profile a cell exposed to perturbagen to identify the genes which are differentially expressed. The differentially expressed genes are analyzed and arranged into an ordered list of identifiers, which along with other instances create a data architecture.

Method of formulating a skin-lightening composition

A method and system for classifying different types of periorbital dyschromia is disclosed. The method includes providing at least one of a predetermined imaging characteristic and a biological characteristic for each of three different types of periorbital dyschromia, and then measuring the appropriate characteristic on a person exhibiting periorbital dyschromia. The type of periorbital dyschromia exhibited by a person can then be determined by comparing the measured value to the predetermined value and selecting the corresponding type of periorbital dyschromia.

Methods of classifying periorbital dyschromia and systems therefor

A method of constructing a data architecture for use in identifying connections between perturbagens and genes associated with skin tone. The method includes providing a gene expression profile for a control cell, generating a gene expression profile for a cell exposed to a perturbagen, identifying genes differentially expressed in response to the perturbagen, creating an ordered list of identifiers, storing the ordered list as an instance on a computer readable medium, and constructing a data architecture of stored instances.

Method of constructing a data architecture

Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADR&#x3b2;1 receptors, and determining based on the binding interaction of the test agent with the ADR&#x3b2;1 receptors whether the test agent is an effective ADR&#x3b2;1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADR&#x3b2;1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.

Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis

A method of identifying a test agent as a skin tone agent. The method includes determining the level of high-mobility group protein B1 (HMGB1), messenger RNA associated with the expression and/or regulation of HMGB1 (HMGB1 mRNA), and/or micro-RNA associated with the expression and/or regulation of HMGB1 (HMGB1 miRNA) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in HMGB1 level, a downregulation in transcription of HMGB1 mRNA, and/or an upregulation of HMGB1 miRNA. The method also includes identifying a test agent as a skin tone agent when the test agent inhibits or prevents an increase in melanocyte dendricity and/or body size caused by HMGB1.

Compositions and methods for inhibiting HMGB1 activation of melanocytes

A method of making a skin composition that includes an effective amount of skin care agent selected to inhibit HMGB1 stimulation of human melanocytes. The method includes determining the level of high-mobility group protein B1 (HMGB1), messenger RNA associated with the expression and/or regulation of HMGB1 (HMGB1 mRNA), and/or micro-RNA associated with the expression and/or regulation of HMGB1 (HMGB1 miRNA) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in HMGB1 level, a downregulation in transcription of HMGB1 mRNA, and/or an upregulation of HMGB1 miRNA. The method also includes identifying a test agent as a skin tone agent when the test agent inhibits or prevents an increase in melanocyte dendricity and/or body size caused by HMGB1, and incorporating the skin tone agent in a dermatologically acceptable carrier.

Method of making a skin care composition

Oral care compositions having improved taste, said compositions comprising: a carrier material; from about 0.001 to about 10%, by weight of the composition, of an oral care component selected from metal salts, antimicrobial agents, bad breath reduction agents, bleaching agents, surfactants, or a combination thereof; and from about 0.0001 to about 1%, by weight of the composition, of a TRPA1 agonist selected from vanillin esters; benzoate esters; hydroxybenzoate derivatives; methoxy benzoate derivatives; hydroxybutanedioate derivatives; benzamidobenzoate derivatives; methylpropanoate derivatives; phenyl acetate derivatives; hex-3-enoate derivatives; 2-(furan-2-ylmethylsulfanyl)-3-methylpyrazine; phenylmethoxymethylbenzene; (2R)-2-azaniumyl-3-[(2R)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate; (3E)-2-hydroxy-4,8-dimethylnona-3,7-dienal; (2R)-2-azaniumyl-3-[(2S)-2-azaniumyl-3-oxido-3-oxopropyl]disulfanylpropanoate; (3Z)-3-butylidene-2-benzofuran-1-one; 3-methyl-N-(3-methylbutyl)butan-1-imine; 2-(furan-2-ylmethyldisulfanylmethyl)furan; and combinations thereof. Uses thereof and methods of improving the taste of an oral care composition.

Growing community of inventors

Mason, OH, United States of America

Wenzhu Zhao